PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation

– European Commission decides against adoption of negative opinion – – Translarna authorization remains active in Europe – – 2024 revenue guidance paused – WARREN, N.J., May 20, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC)…